Respiratory Training for Heart Failure

(PART-HF Trial)

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Lancaster General Hospital

Disqualifiers: Severe COPD, Diaphragm paralysis, Cognitive impairment, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

114 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial tests a breathing therapy for heart failure patients with reduced heart function. The therapy includes using a breathing app and coaching to improve respiratory function and heart health.

Research Team

Roy Small, MD

Principal Investigator

Medical Director

Eligibility Criteria

This trial is for adults with NYHA class II or III heart failure and an Ejection Fraction (EF) of 45% or less. Participants must have been on a stable medical regimen for at least 30 days, be likely to follow the breathing training, have a smartphone with internet, and be under care at Lancaster General Health Penn Medicine.

Inclusion Criteria

Signed informed consent

My medication has been stable for at least 30 days without starting new heart or diabetes drugs.

I am 18 years old or older.

Exclusion Criteria

I have a muscle condition that affects my breathing.

I have had a heart device implanted within the last 6 months.

I cannot or do not want to follow a breathing exercise program.

Treatment Details

Interventions

• Stasis Breathing and Humming Exercises

Trial Overview The study compares standard heart failure care to an added breathing therapy involving Stasis Breathing and humming exercises. It's designed to see if these exercises can help improve symptoms in patients with reduced heart function.

Participant Groups

Group I: HRV4 + Breathing and Humming Training Experimental Treatment 1 Intervention

On a biweekly basis, and with the other members of their subgroup within the cohort, participants will meet with the Meo Health breathing coach on Zoom for approximately 30 minutes. These sessions will encourage participants to complete their daily exercises and provide additional respiratory training.

Group II: HRV4 Only Active Control 1 Intervention

Control participants will complete the daily heart rate variability (HRV) reading using the HRV4Training application.

Who Is Running the Clinical Trial?

Lancaster General Hospital

Lead Sponsor

Trials

25

Recruited

4,100+

Louise von Hess Medical Research Institute

Collaborator

Trials

4

Recruited

380+